Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Angelo Fama

Showing results (1-10 of 27) with videos related to

Pageof 3
Sort By:
American Journal of Hematology|October 27, 2020
SFLT-1 levels in COVID-19 patients: Association with outcome and thrombosisAurelio Negro, Angelo Fama, Domenico Penna, et al.
Leukemia Research|December 17, 2008
WPSS versus simplified myelodysplastic syndrome risk score: Which is the best tool for prediction of survival in myelodysplastic patients?Massimo Breccia, Laura Cannella, Caterina Stefanizzi, et al.
Leukemia & Lymphoma|May 20, 2009
Platelet count is an independent prognostic factor in myelodysplastic syndromes considered as low risk by French-American-British and World Health Organisation classificationsMassimo Breccia, Gianna Maria D'Elia, Laura Cannella, et al.
Cancer Chemotherapy and Pharmacology|November 8, 2008
Isolated molecular relapse in FIP1L1-PDGFRalpha hypereosinophilic syndrome after discontinuation and single weekly dose of imatinib: need of quantitative molecular procedures to modulate imatinib doseMassimo Breccia, Daniela Cilloni, Laura Cannella, et al.
Leukemia Research|April 9, 2015
Anagrelide treatment and cardiovascular monitoring in essential thrombocythemia. A prospective observational studyGiovanni Tortorella, Andrea Piccin, Alessia Tieghi, et al.
Computer Methods and Programs in Biomedicine|November 4, 2019
Texture analysis and multiple-instance learning for the classification of malignant lymphomasMarco Lippi, Stefania Gianotti, Angelo Fama, et al.
International Journal of Hematology|August 25, 2009
Decisional flow with a scoring system to start platelet-lowering treatment in patients with essential thrombocythemia: long-term resultsRoberto Latagliata, Angela Rago, Antonio Spadea, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 25, 2019
A Gene Expression-based Model to Predict Metabolic Response After Two Courses of ABVD in Hodgkin Lymphoma PatientsStefano Luminari, Benedetta Donati, Massimiliano Casali, et al.
Leukemia Research|July 4, 2012
Atypical presentation of anaplastic large T-cell lymphoma mimicking an articular relapse of rheumatoid arthritis in a patient treated with etanercept. A case report and literature reviewFederico De Angelis, Alice Di Rocco, Clara Minotti, et al.
Frontiers in Oncology|March 27, 2023
Comparison of first-line treatment with bendamustine plus rituximab versus R-CHOP for patients with follicular lymphoma grade 3A: Results of a retrospective study from the Fondazione Italiana LinfomiGloria Margiotta-Casaluci, Sara Bigliardi, Federica Cocito, et al.
Pageof 3

Showing results (1-10 of 27) with videos related to

Sort By:
Pageof 3
American Journal of Hematology|October 27, 2020
SFLT-1 levels in COVID-19 patients: Association with outcome and thrombosisAurelio Negro, Angelo Fama, Domenico Penna, et al.
Leukemia Research|December 17, 2008
WPSS versus simplified myelodysplastic syndrome risk score: Which is the best tool for prediction of survival in myelodysplastic patients?Massimo Breccia, Laura Cannella, Caterina Stefanizzi, et al.
Leukemia & Lymphoma|May 20, 2009
Platelet count is an independent prognostic factor in myelodysplastic syndromes considered as low risk by French-American-British and World Health Organisation classificationsMassimo Breccia, Gianna Maria D'Elia, Laura Cannella, et al.
Cancer Chemotherapy and Pharmacology|November 8, 2008
Isolated molecular relapse in FIP1L1-PDGFRalpha hypereosinophilic syndrome after discontinuation and single weekly dose of imatinib: need of quantitative molecular procedures to modulate imatinib doseMassimo Breccia, Daniela Cilloni, Laura Cannella, et al.
Leukemia Research|April 9, 2015
Anagrelide treatment and cardiovascular monitoring in essential thrombocythemia. A prospective observational studyGiovanni Tortorella, Andrea Piccin, Alessia Tieghi, et al.
Computer Methods and Programs in Biomedicine|November 4, 2019
Texture analysis and multiple-instance learning for the classification of malignant lymphomasMarco Lippi, Stefania Gianotti, Angelo Fama, et al.
International Journal of Hematology|August 25, 2009
Decisional flow with a scoring system to start platelet-lowering treatment in patients with essential thrombocythemia: long-term resultsRoberto Latagliata, Angela Rago, Antonio Spadea, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 25, 2019
A Gene Expression-based Model to Predict Metabolic Response After Two Courses of ABVD in Hodgkin Lymphoma PatientsStefano Luminari, Benedetta Donati, Massimiliano Casali, et al.
Leukemia Research|July 4, 2012
Atypical presentation of anaplastic large T-cell lymphoma mimicking an articular relapse of rheumatoid arthritis in a patient treated with etanercept. A case report and literature reviewFederico De Angelis, Alice Di Rocco, Clara Minotti, et al.
Frontiers in Oncology|March 27, 2023
Comparison of first-line treatment with bendamustine plus rituximab versus R-CHOP for patients with follicular lymphoma grade 3A: Results of a retrospective study from the Fondazione Italiana LinfomiGloria Margiotta-Casaluci, Sara Bigliardi, Federica Cocito, et al.
Pageof 3